Janus kinase 2 regulates Bcr-Abl signaling in chronic myeloid leukemia

Leukemia

Volumn 25, Issue 3, 2011, Pages 463-472

  Samanta, A ^a   Perazzona, B ^a   Chakraborty, S ^a   Sun, X ^a   Modi, H ^b   Bhatia, R ^b   Priebe, W ^a   Arlinghaus, R ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Bcr Abl; Bcr Abl ptyrosine 177; chronic myeloid leukemia; Jak2; Jak2 inhibitors

Indexed keywords

BCR ABL PROTEIN; IMATINIB; JANUS KINASE 2; JANUS KINASE 2 INHIBITOR; N TERT BUTYL 3 [5 METHYL 2 [4 (4 METHYL 1 PIPERAZINYL)PHENYLAMINO] 4 PYRIMIDINYLAMINO]BENZENESULFONAMIDE; PHOSPHATIDYLINOSITOL 3 KINASE; RAS PROTEIN; STAT5 PROTEIN; UNCLASSIFIED DRUG; WP 1193;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER INHIBITION; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA CELL LINE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SOLID TUMOR;

EID: 79952437988     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2010.287     Document Type: Article

References (35)

1. Wilson-Rawls J, Xie SH, Liu J, Laneuville P, Arlinghaus RB. P210 Bcr-Abl interacts with the interleukin-3 bc subunit and constitutively induces its tyrosine phosphorylation. Cancer Res 1996; 56: 3426-3430. . (Pubitemid 26251631)
2. Xie S, Wang Y, Liu J, Sun T, Wilson MB, Smithgall TE et al. Involvement of Jak2 tyrosine phosphorylation in Bcr-Abl transformation. Oncogene 2001; 20: 6188-6195. . (Pubitemid 32964431)
3. Xie S, Lin H, Sun T, Arlinghaus RB. Jak2 is involved in c-Myc induction by Bcr-Abl. Oncogene 2002; 21: 7137-7146. . (Pubitemid 35305600)
4. Pear WS, Miller JP, Xu L, Pui JC, Soffer B, Quackenbush RC et al. Efficient and rapid induction of a chronic myelogenous leukemialike myeloproliferative disease in mice receiving P210 bcr/abltransduced bone marrow. Blood 1998; 92: 3780-3792. . (Pubitemid 28525205)
5. Puil L, Liu J, Gish G, Mbamalu G, Bowtell D, Pelicci PG et al. Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway. EMBO J 1994; 13: 764-773. . (Pubitemid 24057507)
6. Sattler M, Mohi MG, Pride YB, Quinnan LR, Malouf NA, Podar K et al. Critical role for Gab2 in transformation by BCR/ABL. Cancer Cell 2002; 1: 479-492. . (Pubitemid 41039128)
7. Steelman LS, Pohnert SC, Shelton JG, Franklin RA, Bertrand FE, McCubrey JA. JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia 2004; 18: 189-218. . (Pubitemid 38240034)
8. Coppo P, Flamant S, De Mas V, Jarrier P, Guillier M, Bonnet ML et al. BCR-ABL activates STAT3 via JAK and MEK pathways in human cells. Br J Haematol 2006; 134: 171-179. . (Pubitemid 43893908)
9. Ilaria Jr RL, Hawley RG, Van Etten RA. Dominant negative mutants implicate STAT 5 in myeloid cell proliferation and neutrophil differentiation. Blood 1999; 93: 4154-4166. . (Pubitemid 29279258)
10. Klejman A, Schreiner SJ, Nieborowska-Skorska M, Slupianek A, Wilson M, Smithgall TE et al. The Src family kinase Hck couples BCR/ABL to STAT5 activation in myeloid leukemia cells. EMBO J 2002; 21: 5766-5774. . (Pubitemid 35315274)
11. Zhang X, Subrahmanyam R, Wong R, Gross AW, Ren R. The NH (2)-terminal coiled-coil domain and tyrosine 177 play important roles in induction of a myeloproliferative disease in mice by Bcr-Abl. Mol Cell Biol 2001; 21: 840-853. . (Pubitemid 32104732)
12. Chu S, Li L, Singh H, Bhatia R. BCR-tyrosine 177 plays an essential role in Ras and Akt activation and in human hematopoietic progenitor transformation in chronic myelogenous leukemia. Cancer Res 2007; 67: 7045-7053. . (Pubitemid 47105554)
13. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN et al. Clinical resistance to STI-571 cancer therapy caused by BCRABL gene mutation or amplification. Science 2001; 293: 876-880. . (Pubitemid 32743979)
14. Branford S, Rudzki Z, Parkinson I, Grigg A, Taylor K, Seymour JF et al. Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations. Blood 2004; 104: 2926-2932. . (Pubitemid 39434981)
15. Saffroy R, Lemoine A, Brezillon P, Frenoy N, Delmas B, Goldschmidt E et al. Real-time quantitation of bcr-abl transcripts in haematological malignancies. Eur J Haematol 2000; 65: 258-266. .
16. Donato NJ, Wu JY, Stapley J, Gallick G, Lin H, Arlinghaus R et al. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 2003; 101: 690-698. . (Pubitemid 36077594)
17. Donato NJ, Wu JY, Stapley J, Lin H, Arlinghaus R, Aggarwal BB et al. Imatinib mesylate resistance through BCRABL independence in chronic myelogenous leukemia. Cancer Res 2004; 64: 672-677. . (Pubitemid 38120909)
18. Tao WJ, Lin H, Sun T, Samanta AK, Arlinghaus R. BCR-ABL oncogenic transformation of NIH 3T3 fibroblasts requires the IL-3 receptor. Oncogene 2008; 27: 3194-3200. . (Pubitemid 351693174)
19. Tao W, Samanta AK, Priebe W, Arlinghaus RB. Enhanced Jak2 activation correlates with IL-3 receptor b Chain expression leading to phosphorylation of tyrosine 177 of Bcr-Abl. Blood (51th Am Soc Hematol Annu Meet Abst) 2009; 114: 854 (abstract 2170). .
20. Samanta AK, Lin H, Sun T, Kantarjian H, Arlinghaus RB. Janus kinase 2: a critical target in chronic myelogenous leukemia. Cancer Res 2006; 66: 6468-6472. . (Pubitemid 44085597)
21. Samanta AK, Chakraborty SN, Wang Y, Kantarjian H, Sun X, Hood J et al. Jak2 inhibition deactivates Lyn kinase through the SET-PP2A-SHP1 pathway, causing apoptosis in drug-resistant cells from chronic myelogenous leukemia patients. Oncogene 2009; 28: 1669-1681. .
22. Samanta AK, Chakraborty SN, Wang Y, Schlette E, Reddy EP, Arlinghaus RB. Destabilization of Bcr-Abl/Jak2 Network by a Jak2/ Abl kinase inhibitor ON044580 overcomes drug resistance in blast crisis chronic myelogenous leukemia (CML). Genes Cancer 2010; 1: 346-359. .
23. Stuart SA, Minami Y, Wang JY. The CML stem cell: evolution of the progenitor. Cell Cycle 2009; 8: 1338-1343. .
24. Minami Y, Stuart SA, Ikawa T, Jiang Y, Banno A, Hunton IC et al. BCR-ABL-transformed GMP as myeloid leukemic stem cells. Proc Natl Acad Sci USA 2008; 105: 17967-17972. .
25. Nicholson E, Holyoake T. The chronic myeloid leukemia stem cell. Clin Lymphoma Myeloma 2009; 9 (Suppl 4): S376-S381. .
26. Jamieson CH. Chronic myeloid leukemia stem cells. Hematology Am Soc Hematol Educ Program 2008, 436-442. .
27. Jorgensen HG, Holyoake TL. Characterization of cancer stem cells in chronic myeloid leukaemia. Biochem Soc Trans 2007; 35 (Pt 5): 1347-1351. . (Pubitemid 350206497)
28. Hansen G, Hercus TR, McClure BJ, Stomski FC, Dottore M, Powell J et al. The structure of the GM-CSF receptor complex reveals a distinct mode of cytokine receptor activation. Cell 2008; 134: 496-507. .
29. Feng J, Witthuhn BA, Matsuda T, Kohlhuber F, Kerr IM, Ihle JN. Activation of Jak2 catalytic activity requires phosphorylation of Y1007 in the kinase activation loop. Mol Cell Biol 1997; 17: 2497-2501. . (Pubitemid 27175130)
30. Huang HM, Lin YL, Chen CH, Chang TW. Simultaneous activation of JAK1 and JAK2 confers IL-3 independent growth on Ba/F3 pro-B cells. J Cell Biochem 2005; 96: 361-375. .
31. Argetsinger LS, Kouadio JL, Steen H, Stensballe A, Jensen ON, Carter-Su C. Autophosphorylation of JAK2 on tyrosines 221 and regulates its activity. Mol Cell Biol 2004; 24: 4955-4967. (Pubitemid 38668059)
32. Liu J, Wu Y, Ma GZ, Lu D, Haataja L, Heisterkamp N et al. Inhibition of Bcr serine kinase by tyrosine phosphorylation. Mol Cell Biol 1996; 16: 998-1005. . (Pubitemid 26061671)
33. Wu Y, Liu J, Arlinghaus RB. Requirement of two specific tyrosine residues for the catalytic activity of Bcr serine/threonine kinase. Oncogene 1998; 16: 141-146. . (Pubitemid 28043518)
34. Maru Y, Witte ON. The BCR gene encodes a novel serine/threonine kinase activity within a single exon. Cell 1991; 67: 459-468. . (Pubitemid 121001461)
35. Pardanani A, Hood J, Lasho T, Levine RL, Martin MB, Noronha G et al. TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations. Leukemia 2007; 21: 1658-1668. (Pubitemid 47086756)